News & Updates
VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of…
Read More
Excerpt from the Press Release: BLUE BELL, Pa.–(BUSINESS WIRE)–The Canadian Life Science and Technology Park, Allyant, and IPS are proud to announce a strategic, multi-year partnership focused on the advancement of the design and engineering of a state-of-the-art Life Science, Healthcare, and Technology Park. This collaboration brings together expertise in design and construction oversight tailored…
Read More
New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research Excerpt from the Press Release: BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs. “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive…
Read More
– First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) – – Phase 2a portion of Phase 1/2a clinical trial will evaluate IMM-1-104 as monotherapy in PDAC, non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC – – Topline data…
Read More
Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / March 11, 2024 / Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”), (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the first Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by the independent DSMB. This…
Read More
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive markers of liver injury and fibrosis and of metabolic health Results indicate potential of EFX to improve resolution of steatohepatitis and fibrosis for…
Read More
Drug Combination’s Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition Excerpt from the Press Release: SAN CARLOS, Calif. & LISBON, Portugal–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a data with…
Read More
Excerpt from the Press Release: SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?